Fate Therapeutics Inc (FATE)

Nov 23, 2024

Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World

Nov 23, 2024

Nov 21, 2024

Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com

Nov 21, 2024

Nov 20, 2024

FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN

Nov 20, 2024

Nov 20, 2024

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha

Nov 20, 2024

Nov 20, 2024

Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN

Nov 20, 2024

Nov 19, 2024

Needham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Nov 19, 2024

Nov 19, 2024

Fate Thera rockets on early data for FT819 - The Pharma Letter

Nov 19, 2024

Nov 18, 2024

Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com

Nov 18, 2024

Nov 18, 2024

BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK

Nov 18, 2024

Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance

Nov 18, 2024

Nov 15, 2024

Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat

Nov 15, 2024

Nov 15, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Fate Therapeutics stock hits 52-week low at $2.09 By Investing.com - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges - TipRanks

Nov 14, 2024

Nov 13, 2024

Fate Therapeutics Unveils Q3 2024 Financial Highlights - TipRanks

Nov 13, 2024

Nov 13, 2024

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance

Nov 13, 2024

Nov 13, 2024

BMO cuts Fate Therapeutics stock target, keeps market rating on initial data - Investing.com UK

Nov 13, 2024

Nov 13, 2024

Fate Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 13, 2024

Nov 12, 2024

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK

Nov 12, 2024

Nov 12, 2024

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 12, 2024

Nov 12, 2024

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times

Nov 12, 2024

Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - The Manila Times

Nov 09, 2024

Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, - GlobeNewswire

Nov 09, 2024

Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewswire Inc.

Nov 09, 2024

Nov 08, 2024

Fate Therapeutics Presents Pan-tumor Targeting Preclinical - GlobeNewswire

Nov 08, 2024

Nov 08, 2024

Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat

Nov 08, 2024

Nov 08, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Nov 08, 2024

Nov 07, 2024

Fate Therapeutics Inc (FATE) Worth Considering For The Next Few Weeks - Stocks Register

Nov 07, 2024

Nov 07, 2024

Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register

Nov 07, 2024

Nov 04, 2024

Global T-cell Therapy Market Trend [2024-2032] | Consumer Demographics - WICZ

Nov 04, 2024

Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024

Oct 25, 2024

Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St

Oct 25, 2024

Oct 22, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne

Oct 22, 2024

Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024

Oct 16, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat

Oct 16, 2024

Oct 16, 2024

Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News

Oct 16, 2024

Oct 15, 2024

Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News

Oct 15, 2024

Oct 14, 2024

Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex

Oct 14, 2024

Oct 14, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 14, 2024

Oct 09, 2024

Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily

Oct 09, 2024

Oct 09, 2024

Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 09, 2024